CX3CL1 release during immunogenic apoptosis is associated with enhanced anti-tumour immunity
IntroductionImmunogenic cell death (ICD) has emerged as a novel option for cancer immunotherapy. The key determinants of ICD encompass antigenicity (the presence of antigens) and adjuvanticity, which involves the release of damage-associated molecular …